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Abstract
Hypoxia is known to influence the cell cycle by increasing the G1 phase
duration or by inducing a quiescent state (arrest of cell proliferation). This
entry into quiescence is a mean for the cell to escape from hypoxia-induced
apoptosis. It is suggested that some cancer cells have gain the advantage over
normal cells to easily enter into quiescence when environmental conditions,
such as oxygen pressure, are unfavorable [43, 1]. This ability contributes in
the appearance of highly resistant and aggressive tumor phenotypes [2].
The HiF-1α factor is the key actor of the intracellular hypoxia pathway.
As tumor cells undergo chronic hypoxic conditions, HiF-1α is present in
higher level in cancer than in normal cells. Besides, it was shown that genetic
mutations promoting overstabilization of HiF-1α are a feature of various
types of cancers [8]. Finally, it is suggested that the intracellular level of
HiF-1α can be related to the aggressiveness of the tumors [53, 24, 4, 10].
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However, up to now, mathematical models describing the G1/S transition
under hypoxia, did not take into account the HiF-1α factor in the hypoxia
pathway.
Therefore, we propose a mathematical model of the G1/S transition un-
der hypoxia, which explicitly integrates the HiF-1α pathway. The model
reproduces the slowing down of G1 phase under moderate hypoxia, and the
entry into quiescence of proliferating cells under severe hypoxia. We show
how the inhibition of cyclin D by HiF-1α can induce quiescence; this result
provides a theoretical explanation to the experimental observations of Wen et
al. (2010). Thus, our model confirms that hypoxia-induced chemoresistance
can be linked, for a part, to the negative regulation of cyclin D by HiF-1α.
Keywords: Hypoxia, HiF-1α, G1/S transition, quiescence, cell cycle arrest,
cancer
1. Introduction
The integration of environmental factors influencing cell proliferation is
the actual challenge of cell cycle modeling [12]. Indeed, since the 1990’s, many
models were developed to describe the evolution of protein levels during the
cycle [36, 11, 5, 52]. However, few of them take into account external param-
eters, such as the temperature, the mechanical properties of the substrate, or
hypoxia. This last factor is particularly interesting to study. In physiological
conditions, hypoxia can occur if the blood does not bring enough oxygen to
the cells. If hypoxia is too severe or too long, the cell enters into apopto-
sis [23]. In pathological conditions, cancer cells undergo a chronic hypoxia
[30, 31]. This hypoxia induces more aggressive, metastatic and resistant
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tumors [23, 25]. In particular, if hypoxia can induce apoptosis in normal
proliferating cells, tumor cells resist to apoptosis [23]. One mechanism that
can explain this resistance is the entry into a quiescent state, where the cell
stops its division cycle [43, 2]. This quiescent state is also a mean for the
cancer cell to escape from the effects of chemotherapy [2, 33, 40]. Therefore,
it participates to the aggressiveness of the tumors.
Alarcon et al. [1] proposed a simple model explaining why cancer cells can
enter into quiescence under hypoxic conditions whereas normal cells follow
their cycle. The authors introduce a difference between normal proliferating
and cancer cells through the deregulation of the expression of a protein of
the cell-cycle (p27) during tumorigenesis. However, this deregulation event
is not a general feature of cancer. Indeed, this phenomenon was not observed
in the majority of tumor cells [32, 39]. Besides, it is not clear that p27 is
necessary to induce hypoxia-induced cell cycle arrest [6, 21].
The HiF-1α factor is the central protein involved in the intracellular sig-
naling pathway of hypoxia [46]. It is a transcription factor, which enhances
the expression of numerous genes. These genes enable the cell to adapt to
the environmental conditions (angiogenesis, arrest of aerobic metabolism),
or to enter into apoptosis [20, 37].
HiF-1 is an heterodimeric protein, constituted of two sub-units: HiF-1β,
which is constitutively expressed, and HiF-1α, which is the sensor of hypoxia.
Indeed, in order to activate hypoxia genes, HiF-1α has to be in a reduced
form. When the level of oxygen is sufficient, an enzyme called HiF-1α prolyl-
hydroxylase is active and converts HiF-1α into an hydroxylated form. This
oxygenated form of HiF-1α is rapidly degraded by the proteasom pathway
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[23, 44, 40].
The ways of actions of HiF-1α are numerous and complex [38]. A review
of the huge molecular biology literature dealing with the effects of HiF-1α on
the cell cycle enables us to retain several types of actions. First, it is clear
that HiF-1α indirectly downregulates cyclin E activity, and this inhibition is
the reason why HiF-1α causes slowing down or arrest of cell cycle [22, 19, 1].
The origins of this action on cyclin E activity remain poorly defined [22],
even if some potential pathways are known. Notably, the upregulation of
cyclins inhibitors, such as p21 and p27, are reported [17, 22, 20]. However,
some authors showed that the action of HiF-1α on p27 is not so clear since
the expression of p27 under hypoxia may be independent of HiF-1α [6, 9].
The second important effect of HiF-1α is the interrelation between this
factor and cyclin D [50, 16]. Wen et al. [50] studied the effect of HiF stabi-
lization on cyclin D level. They first found that after 24h at 0.2%, the mean
cylin D concentration in the whole cell population decreases with 50% com-
pared to the normoxic condition. To confirm the implication of HiF-1, its
activity was impaired by DN-HiF overexpression, which induces an increase
of the cyclin D level. There is also an action of cyclin D on HiF-1α, due
to the activation of the HiF-1 prolyl-hydroxylase activity [16]. Besides, the
activation of cyclin D expression by HiF-2 underlines the rivalry in hypoxic
tumor growth and progression between HiF-1 and HiF-2. Here, we choose to
focus on the influence of cyclin D inhibition by HiF-1α, in order to show how
this simple relationship can generate a serie of interesting results in agree-
ment with data from the literature. Besides, the inhibition of the cyclins
by HiF-1α under hypoxia is very well documented. As we previously said,
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hypoxia-dependent inhibition of cyclin E is considered as a cause of hypoxia-
dependent cell-cycle arrest. Second, the increase of unphosphorylated versus
phosphorylated form of the Retinoblastoma protein [19, 20] under hypoxia
is also a good evidence for the downregulation of cyclin D by HiF.
The increase of HiF-1α activity during tumorigenesis is well documented,
since it seems to be a very common feature of cancers [53, 29, 7, 42]. As a
consequence, this factor became a new therapeutic target [45, 47]. In some
cases, its high level is simply due to the chronic hypoxia undergone by the
tumor cells. In other cases, genetic mutations induce an over-stabilization of
HiF-1. It is the case for the renal clear carcinoma [13]. As a consequence,
for the same oxygen pressure, HiF-1 will have a higher level in cancer cells
than in normal cells [15].
In a general way, a link was found between the aggressiveness of cancers
and HiF-1α activity. This role of HiF in tumorigenesis is firstly due to the
induction of anti-apoptotic and pro-angiogenic genes. Second, it mediates
the entrance into quiescence of proliferating cells, which induces a hypoxia-
dependent chemoresistance.
The aim of this work is to describe an example of a simple mechanism of
HiF-1α-dependent entrance into quiescence under hypoxia. We make a link
between the level of HiF-1α and the ability of the cell to enter into quiescence
under hypoxia. In agreement with the literature, our model assumes the
regulation of HiF-1α stability by the oxygen pressure [51, 44, 34]. We built
a mathematical model of the G1/S transition in hypoxic conditions, which
explicitly integrates the HiF-1α pathway. We focused on the relationships
between HiF-1α and the cyclins, in order to propose a simple and biologically
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accurate mechanism of hypoxia-induced quiescence.
2. Model
2.1. Hypotheses
Our model is primary based on the models described in Alarcon et al.
[1], Tyson and Novak [49], Novak and Tyson [36]. In those papers, the G1/S
transition is modeled by a biological switch between a cyclin and an inhibitor
complex. They considered that this inhibitor was APC/cdh1. However, this
role of APC/cdh1 complex is not well admitted; classicaly, the complex ad-
dressing cyclin E for degradation is known to be the SCF complex [14]. As
a consequence, it is more accurate to consider that the inhibitor of cyclin E
is SCF. The switch that we aim to study is represented in Figure 1. The G1
phase finishes when this molecular switch occurs. In our model, we differen-
tiate the cyclin E and the cyclin D. The cyclin E is involved in the molecular
switch where it inhibits and is inhibited by the SCF complex. Whereas
Novak and Tyson [36] consider that two cyclins drive the G1/S transition
(cyclin E and A), we consider here just one cyclin we named cyclin E. The
concentration in active SCF complex is controlled by an evolution equation
similar to that given by Tyson and Novak [49] for the APC/cdh1 complex.
The cyclin D phosphorylates the Rb protein, which releases the transcrip-
tion factor E2F. As Novak and Tyson [36], we supposed that at each time,
E2FRb is in an equilibrium relationship with E2F and Rb because the com-
plexation/decomplexation of phopshorylated Rb and E2F are supposed to be
very fast compared to the evolution of the cyclin concentration. Besides, free
E2F can be in an unphosphorylated (active) form, or in a phosphorylated
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(inactive) form. A dynamic equilibrium ensures the transition from phos-
phorylated to unphosphorylated forms. The total concentration of E2F (free
phosphorylated/unphosphorylated, and complexed with Rb) is supposed to
be constant, as in [36]. Active E2F factor promotes the synthesis of the cyclin
E, as assumed for the cyclin A by Novak and Tyson [36]. Besides, to take into
account the cell growth in the progression through the G1 phase, we assume
that the mass increases the cyclin E concentration. This assumption is taken
from Alarcon et al. [1] and Novak and Tyson [36]. The oxygen pressure
is taken into account with the variable P , which represents the percentage
of oxygen among all the other gases in the cell environment. The effect of
the oxygen pressure is modeled by the concentration of HiF-1α. This con-
centration increases when the oxygen pressure decreases, as well described
in the literature [27, 54]. Jiang et al. [27] show that in vitro cultured cells
submitted to hypoxia exhibit an exponential relationship between the HiF-1
level and the oxygen pressure [27]. The experimental results from Zhou et
al. [54] confirm that an exponential law is a good model for the hypoxia-
induced HiF-1 stabilization. These authors also showed that this exponential
law strongly depends on the cancer cell lines. We will discuss this point later.
HiF-1α decreases the cyclin D activity by inhibiting its synthesis, as observed
in experiments [50]. The evolution of the cyclin D level during the cycle, the
influence of HiF-1α on its level, and the reaction of Rb phosphorylation are
calibrated with data from the literature. We do not take into account the
role of the p27 protein, contrary to Alarcon et al. [1]. As we said, the ef-
fects of hypoxia on this protein remain unclear; besides, we want to focus on
the influence of cyclin D/HiF interactions which promote the entrance into
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quiescence. Figure 2 gives a sketch of the molecular network.
2.2. Biological description
The variables used in the model are the cyclin D (cycD), the cyclin E
(cycE), the Retinoblastoma protein (in its unphosphorylated form) (Rb),
HiF-1α (H), the SCF complex (SCF ), the mass of the cell, and the different
chemical forms of the E2F transcription factor. E2F exists in phosphorylated
and unphosphorylated (E2F ) form, and free or linked to Rb (E2FRb). Thus,
free E2F can be phosphorylated or unphosphorylated. The free and unphos-
phorylated form (E2FA) is the active form. A chemical equilibrium drives
the transition between the phosphorylated and unphosphorylated forms of
E2F. We named E2Ftot the total of all the chemical forms of E2F. As Novak
and Tyson [36], we assume this total to be constant. The cyclin D liberates
E2F by phosphorylating Rb (that is to say by decreasing [Rb]). E2FA has
a crucial role, since it promotes the synthesis of the cyclin E. Cell growth is
the second factor influencing the cyclin E synthesis, trough the variable m.
HiF-1 inhibits the cyclin D synthesis. As a consequence, hypoxia induces a
decrease of E2FA maximal level, which decreases the synthesis rate of the
cyclin E. The core of the model is the molecular switch between the cyclin
E and its inhibitor (SCF). Following the same idea as Novak and Tyson [36]
and Alarcon et al. [1], this switch is driven by the mutual inhibition of SCF
and the cyclin E.
2.3. Mathematical formulation
The model can be written with a system of coupled ordinary differential
equations (ODEs).
8
The cyclin D is synthesized with rate a1 and naturally degraded with rate
a2. We assume that it is linearly decreasing with [H] [50]:
d[cycD]
dt
= a1 − a3[H]− a2[cycD] (1)
The synthesis of cyclin E is induced by the cell growth and E2FA, ac-
cording to Novak and Tyson [36] and Alarcon et al. [1]. Its degradation is
stimulated by the SCF complex:
d[cycE]
dt
= b1m[E2FA]− b2[cycE]− b3[cycE][SCF ] (2)
The SCF complex obeys the same equation as the APC/cdh1 complex of
the previous models [1, 36, 49]:
d[SCF ]
dt
=
e1(1− [SCF ])
J1 + 1− [SCF ]
− e2
[SCF ][cycE]
J2 + [SCF ]
(3)
As in Alarcon et al. [1], Rb (unphosphorylated Rb) is synthetized with a
d2 rate, and naturally degraded with a d3 rate. The cyclin D phosphorylates
Rb. As a consequence, [Rb] decreases:
d[Rb]
dt
= d2 − (d3 + d1[cycD])[Rb] (4)
The growth of the cell mass follows the same law as in Alarcon et al. [1],
with a growth rate α and a maximal size m0:
dm
dt
= αm(1−
m
m0
) (5)
The unphosphorylated form of E2F follows a dynamic equilibrium de-
scribed by Novak and Tyson [36]:
d[E2F ]
dt
= g1([E2F ]tot − [E2F ]) (6)
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The equilibrium relationship between the oxygen pressure and the HiF-1α
concentration has been derived from experiments [27]:
[H] = H0e
β1(1−P ) (7)
Following Novak and Tyson [36], we assume that at each time, the active
E2F is the fraction of unphosphorylated ( [E2F ]
[E2F ]tot
) free ([E2F ]tot − [E2FRb)
E2F factor:
[E2FA] =
([E2F ]tot − [E2FRb])[E2F ]
[E2F ]tot
(8)
The equilibrium between E2FRb, E2F and Rb is given by the equation
from Novak and Tyson [36]:
[E2FRb] =
2[E2F ]tot[Rb]
[E2F ]tot + [Rb] +
√
([E2F ]tot + [Rb])2 − 4[E2F ]tot[Rb]
(9)
As in previous models, the core of the system is the molecular switch
between a cyclin and SCF. Mathematically, we consider that the cell passes
through the G1 phase when [cycE] > [cycE]threshold and [SCF ] < [SCF ]threshold.
We chose [SCF ]thresold = 0.004 and [cycE]thresold = 0.15. When these values
are reached, the cell divides.
Inhibition of the cyclin D by HiF-1α. Eq.(1) and (7) describe the relationship
between the cyclin D, HiF-1α and the oxygen pressure P in the cell environ-
ment. This model considers the effects of a long term (almost 48h) hypoxia.
Thus, the level of HiF is stabilized. The cyclin D is synthesized with rate a1,
and degraded with rate a2. Its synthesis is inhibited by HiF-1α, which con-
centration depends on oxygen pressure following the expression given in eq.
(7). The parameter a3 represents the action of HiF on the synthesis of cyclin
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D. The parameter β1 is determined from Jiang et al. [27] (see Appendices
A). The variable P stands for the oxygen pressure in the cell environment,
expressed as a normalized percentage of all the gases. As suggested by Jiang
et al. [27], we consider that the reference pressure (P=1) is 6% O2. All the
pressures will be normalized with this reference pressure. The parameters
a1, a2 and a3 are estimated with data coming from Wen et al. [50] and Yang
et al. [52] (see Appendix A).
Control of E2F concentration. We denote [E2F ]tot the total concentration
of E2F, E2FRB the complex E2F/Rb, E2F the unphosphorylated form of
E2F and E2FA the free and unphosphorylated (active) form. We describe
the equilibrium between these different variables from Eqs.(6),(8),(9) previ-
ously proposed by Novak and Tyson [36]. The first describes the transition,
mediated by g1, from phosphorylated to unphosphorylated E2F. The others
are equilibrium equations modeling the relationship between the different
chemical species involving E2F.
Eq.(4) describes the evolution of the unphosphorylated Retinoblastoma
protein concentration. [Rb] is synthesized with coefficient d2, naturally phos-
phorylated in the cell environment with coefficient d3, and phosphorylated
by the cyclin D with coefficient d1.
Molecular switch. Eqs.(2),(3) describe the biological switch which forms the
core of the model for the G1/S transition. Besides, we suppose that the
synthesis of cyclins E, represented by the variable cycE in our model, depends
on the mass m and on the transcription factor E2F in its active form (E2FA)
[36]. The parameter b1 regulates the speed of the chemical synthesis. In the
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other hand, cycE is naturally degraded with coefficient b2, and suffers SCF-
mediated degradation with coefficient b3. The aim is to simulate a switch
similar to that obtained in these previous models of the G1/S transition.
As in Novak and Tyson [36], the dynamics of the inhibitor depends on the
cyclin E, and on the transition between an active and an inactive form. These
dependencies are expressed through Michaelis-Menten terms with enzymatic
constants J1 and J2 respectively. The parameter e1 promotes the transition
from inactive to active forms, and e2 the transition from active to inactive
forms.
Parameters. The parameters we used are given in Table 1. Their values were
estimated from previous models [1, 36] and experimental data of molecular
biology taken from the literature (see Appendix A). We will show that we
can reduce the variability of all the parameters to the variability of e2 and α,
which control the dynamics of the system. These parameters can be easily
adjusted to biological data.
3. Results
We simulated the G1/S transition by solving the system of equations
Eqs.(1)-(9) for different values of P . We used a standard fourth order Runge-
Kutta method, implemented in Matlab. The values of the parameters used
in our first simulations are given in Table 1. We chose the undetermined
parameters in order to have a G1 phase duration of about 400 minutes. This
duration was chosen based on the work of Novak and Tyson (2004) [36]. The
rise of cyclins D and A levels, which was interpreted by Novak and Tyson,
and by ourselves, as the signal for the G1/S transition, occurs about 6-7
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hours after the beginning of the cycle. The initial conditions we used are
given in Table 2. The initial values for the concentrations were chosen to
have values of the same order of magnitude to that used by Alarcon et al.
[1] and Novak [36]. We can notice that the initial concentrations do not
influence the final state of the system (see Appendices B). We consider that
the cell passes through the G1 phase when [cycE] > [cycE]threshold = 0.15
and [SCF ] < [SCF ]threshold = 0.04. These threshold conditions were chosen
to capture as precisely as possible the moment of the switch between the
cyclin E and the SCF complex. In the rest of the paper, the notation [X]∞
stands for the value of [X] when the system reaches its steady state.
3.1. Hypoxia induces entrance into quiescence
Figure 3 shows simulations of the G1/S transition under three levels of
hypoxia. When P diminishes, the molecular switch occurs with a delay which
increases when hypoxia becomes more severe. For a certain value of P (here,
0.01), this switch does not occur any more. As in [1], this inability for the cell
to pass through the G1 phase can be interpreted as the entry into the qui-
escent state. P ∗ denotes the minimal pressure which enables the cell to pass
through the G1 phase.The parameters are given in Table 1, and P ∗ = 0.03.
We also plotted the duration of the G1 phase as a function of P (Figure
4). As hypoxia becomes more intense, the G1 phase duration increases, in
agreement with the literature [17]. For the lowest value of the pressure, we ob-
serve an asymptotic behavior, which finishes by the entrance into quiescence.
In order to mathematically characterize the final state of the cell (quies-
cent or proliferating), the stationary state solutions of the system, depending
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on P , are numerically calculated. The details of the calculation are presented
in the Appendices B. Figure 5 presents the stable stationary states of the sys-
tem as a function of P . When P < P ∗, the system exhibits three stable sta-
tionary states. With our initial conditions ([SCF ] high and [cycE] low), the
equilibrium state of the system is reached with [SCF ] > [SCF ]threshold and
[cycE] < [cycE]threshold. This situation corresponds to the quiescent state.
When P > P ∗, the system has a unique stationary state. It is characterized
by a high level of cycE and a low concentration of SCF , which leads the cell
to achieve its cycle.
3.2. Influence of parameters variability
Previous observations enable us to suppose that the two main features of
the cell response to hypoxia are the increased duration of the G1 phase and
the capacity to enter into quiescence. The latter can be quantified by the
value of P ∗ (pressure for the bifurcation of the dynamics system). The core
of the system is the molecular switch due to SCF and cycE interactions.
The variations of P have an influence on these dynamics by changing [E2FA]
and m. Since these two variables determine the synthesis rate of cycE, they
affect the G1 phase duration and equilibrium values of SCF and cycE.
The equilibrium value of m never changes in our model. We call this
maximal mass value m0, and we have m∞=m0. We can simulate its influence
on the dynamics of the system by modifying b1, which buffers the variations
of m0 in the production rate of cycE. Therefore, we do not consider m0 as a
key parameter for the dynamics of the system. The variations of the growth
rate, by modifications of the parameter α, just have an influence on the cell
cycle duration.
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Final concentrations of the SCF and cycE directly depend on [E2FA]∞.
We can express [E2FA]∞ as a function of [cycD]∞, d1, d2 (see Appendix B).
[cycD]∞ depends on the parameters of Eq.(1) and (7) (a1, a2, a3, β1). As a
consequence, the variability of all these parameters is totally buffered by the
variability of b1, which controls the production rate of cycE.
As it ensures the coupling between SCF and cycE, the parameter e2
also controls the dynamics of the molecular switch. If the coupling is weak,
it is more difficult for the system to generate a molecular switch. As a
consequence, we can also consider the parameter e2 as a key factor influencing
the behavior of the system.
Finally, the whole variability of the adjustment parameters can be simu-
lated by the variability of the parameters e2, b1 and α.
Figure 6 shows that the (b1, e2) couple determines the value of P
∗. When
e2 decreases, the coupling between SCF and cycE becomes weak, and it is
necessary to increase the hypoxic level to observe quiescence. As a conse-
quence, P ∗ decreases. In parallel, when b1 decreases, the production rate of
cycE at the steady state is less important. Therefore, the cell enters more
easily into quiescence, and P ∗ increases. We note that, for a given value of
b1, the variations of e2 are sufficient to simulate a large panel of values for
P ∗. As a consequence, in order to adjust the model to a given value of this
limit pressure, we can set b1 and consider e2 as an adjustment parameter. Fi-
nally, the parameters controlling the dynamics of the system are e2 (coupling
between cyclin E and SCF) and α (growth rate).
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4. Discussion
This paper proposes a mathematical model of the G1/S transition in
hypoxic conditions. Our model was calibrated with data from the literature,
and the results from other mathematical models of the G1 phase transition
[1, 36]. The core of this model is a molecular switch between a cyclin and
an inhibitor (SCF). The passage through the G1 phase is determined by the
possibility to realize this switch. If the switch does not occur, we consider
that the cell is trapped into a quiescent state. Hypoxia was simulated by
introducing HiF-1α. We modeled the inhibition between cyclin D and HiF-
1α, in agreement with data from the literature [50]. The oxygen pressure
determines, in this way, the final concentration of cyclins D during the G1
phase. This level of cyclins D determines the maximum value of the active
E2F concentration, which controls the synthesis rate of cyclins E. If this rate
is not high enough, the critical concentration for the cyclin E is not reached
and the molecular switch cannot occur. The cell enters into a quiescent state.
As a consequence, if the oxygen pressure is low, the cyclin D will not reach
a sufficient level to ensure the minimal amount of cyclins E the cell needs
to achieve the G1 phase. We could define a limit pressure P ∗, which is the
minimum oxygen pressure whereby the cell can pass through the G1 phase.
Mathematically, it corresponds to the bifurcation point of our system.
Thus, this model illustrates a simple mechanism of hypoxia-mediated
slowing down of the cell cycle, and entrance into quiescence. It focuses on the
influence of the interactions between HiF-1α and the cyclins on the G1 phase
achievement. Notably, we show how the inhibition of cyclin D by HiF-1α can
affect the cell cycle. By inhibiting the cyclin D activity, HiF promotes the
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entrance into quiescence. Thus, it provides a resistance to apoptosis for the
proliferative cells. This result gives an explanation to the results of Wen et al.
[50], which have shown that the HiF-mediated chemoresistance appearing in
tumor cells is linked to the inhibition of the cyclin D. Indeed, they observed
that the inhibition of cyclin D expression by siRNA induces an increase of
the resistance to chemically-induced apoptosis. They concluded than the
negative regulation of the cyclin D induced by HiF can, at least partially,
explain the chemoresistance which is associated to cancerous HiF-1 over-
stabilization. Thus, our model shows how a certain form of chemoresistance
can be associated to HiF-1 in cancer cells. In the case of a similar response to
hypoxia between normal and cancer cells (non-mutated hypoxia pathway),
the model highlights a possible mechanism for the chronic hypoxia-induced
entry into quiescence.
In the case of a genetic over-stabilization of HiF-1, which is the case
for various type of cancers [13, 8], the increased ability of cancer cells to
enter into a quiescent state is well described by our model. Indeed, this case
can be modeled by multiplying [H0] by an ǫ > 1 parameter to artificially
increase the HiF-1 level. As a consequence, for a same oxygen pressure, HiF-
1 concentration will be more important in cancer cells than in normal cell.
Thus, for a given hypoxic condition, a cancer cell can enter into a quiescent
(resistant) state whereas the normal cells continue their cycle (more sensitive
to apoptosis). Our model thus captures the differential behavior of cancer
and normal cell. We can notice than this ǫ parameter could depend on the
cell line, since Zhou et al. [54] showed that different cancer cell lines does
not have the same normoxic level of HiF-1.
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Compared to the model from Alarcon et al. [1], our work describes in
a very general way the influence of HiF-1 on hypoxia-induced quiescence of
normal and cancer cells. Whereas the previous model was based on an ar-
guable action of hypoxia on p27, we constructed a biologically more accurate
system of ODEs. This new model gives a possible explanation to the link
between HiF-1, the cyclins and hypoxia-induced chemoresistance. Besides,
our model can easily be completed to study the influence of a genetic over-
stabilization of HiF-1 by considering an ǫ parameter, which can vary with
the considered cell line.
The α parameter, which drives the growth speed of the cell, was chosen
to obtain a value of 400min for the G1 phase duration. It is important to
notice that the results of our model are not influenced by the choice of the
normoxic G1 phase duration. Since it does not influence the final state of
the mathematical system, this α parameter can be modified to adjust the
model to various G1 phase durations. It is biologically correct, because the
duration of the G1 phase in the absence of an environmental stress is known
to be, at least for a part, driven by the growth rate of the cell [5].
Besides, the influence of HiF-1 on the cell metabolism was not taken into
account in this model. It is known that the glycolitic switch described by
Gatenby and Gillies (2004) [18] is linked to the activity of HiF-1. Notably, it
was shown that HiF-1 stimulates the synthesis of glycolitic enzymes, such as
Pyruvate Kinase [37]. In parallel, Icreverzi et al. [26] observed that the cyclin
D enhances the cell growth through the stimulation of mitobiogenesis. By
inhibiting the synthesis of cyclins D, HiF-1 makes the mitobiogenesis to de-
crease, which promotes the transition to a glycolytic phenotype. This switch
18
allows cancer cells to compensate low aerobic metabolism by an increased
glucose consumption. This can be a way for the cell to escape the quiescence
state. It could be interesting to add to our model a term describing the
energetic production, and to link the cell growth to this available energy.
We also have to notice that our model only studies the effect of a given
oxygen pressure on a single cell. In the reality of tumor growth, there is a
gradient of oxygen which varies in space and time. To study the effects of
such a dynamical hypoxic condition, it would be necessary to consider some
series of cycles, by resetting the values of the variables to their initial values
after the G1/S transition is reached. For each new cycle, the oxygen level
can change, and the cell response may also change.
Besides, it is possible to extend this model to consider a population of
interacting cells. These interactions can be, for instance, through the dif-
fusion of growth factors which stimulate cell proliferation by enhancing the
synthesis of cyclins D [51]. We can also consider the differential mechani-
cal interactions between the tumor cells, and between tumor cells and the
stroma. These mechanical interactions are known to influence cell division
[41].
We can notice here that the kinetics of HiF-1 accumulation is not con-
sidered in this model. We study the idealized case of a constant hypoxia,
and we consider the effect of the equilibrium value of HiF-1. However, these
kinetics were measured ([35, 28]). HiF-1 shows a peak after 6h, and then
decreases to stabilize at an equilibrium level after 24-48h. This equilibrium
level depends on the intensity of hypoxia, and on the cellular type (normal
and cancer cells). If we consider the more complex case of a dynamical hy-
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poxia, it should be necessary to take into account these kinetics of HiF-1
accumulation.
We note that the exact relationships between HiF-1 and the cyclin D is
not totally elucidated. Many reports show that HiF-1 inhibits the cyclin D
[50, 16] and the cyclin E [22, 19, 1] leading to the cell cycle arrest. However,
an other report [3] shows that HiF-1 can also stimulate the induction of
cyclins D, leading to cell proliferation. In our work, we use the first biological
hypothesis, and we show that it can explain the cell cycle arrest phenomenon
that is commonly observed.
Finally, we aim to calibrate the undetermined parameters with experi-
mental data, by measuring the G1 phase duration under hypoxia and the
value of P ∗. Since we showed that only two parameters (α and e2) drive the
dynamics of the system (G1 phase duration and entrance into a quiescence
state), experimental data will enable us to set the values of these parameters
for different cell lines. Therefore, this would provide a tool to compare dif-
ferent cancer cell lines on the basis of their ability to enter into a quiescence
state. It could be interesting to build up a classification of different cancer
cells using the values of the parameters of our model. By comparing it with a
known classification made on the basis of their resistance and aggressiveness,
we could obtain some information about the correlation between the ability
to enter into quiescence under hypoxia and the aggressiveness.
Acknowledgements
We are very grateful to Franc¸oise Giroud for her advices which helped us
to build and justify the hypotheses of the model.
20
parameter Value Reference
a1 0.51 [48], [36]
a2 1 [48], [36]
a3H0 0.0085 [50]
β1 2.5 [27]
b1 0.018
b2 0.5 [1]
b3 1 [1]
J1 0.04 [1]
J2 0.04 [1]
d1 0.2 [36]
d2 0.1 [1]
e2 14
e1 1
α 0.005
g1 0.016 [36]
[E2F]tot 1
[cycE]threshold 0.15 [1]
[SCF ]threshold 0.004 [1]
Table 1: Parameters used in the model. The parameters we could not estimate are initially
determined in order to reach a G1 phase duration of about 400 min for proliferative cells
in normoxic conditions
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Model’s variables Notations Initial Value
Masse m 5
Cyclin D cycD 0.1
Non-phosphorylated Rb Rb 1
Cyclin E cycE 0.01
SCF complex SCF 0.9
Unphosphorylated E2F E2F 0.1
Table 2: Initial values taken for the simulations
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Appendix A. Determination of the parameters
The parameter we did not adjust were taken from [1] and [36] models, or
calculated from the molecular biology literature. This first part presents the
biological data used to build the model.
Appendix A.1. HiF-1α and oxygen pressure
In [27] the relationship between [H] (HiF-1 concentration) and P was
experimentally determined. The authors have shown that the level of HiF-1α
varies with oxygen pressure in an exponential form, when the oxygen pressure
is below 6%. The experimental curve they present was fitted in order to build
the dimensionless expression describing the relationship between [H] and P .
The normoxia (P=1) is reached for an oxygen pressure P=6%.
Appendix A.2. Hif-1α and cyclin D dynamic
In [48], the level of cyclin D is quantified during the cycle: the protein
is multiplied by a factor taken between 2 and 5 during the G1 phase. We
adjust the maximum level of cyclin D to reach a concentration five times
higher than in the beginning of the G1 phase. We also used the dynamic of
the cyclin D evolution during the G1 phase modeled by [36], with a rapid
increase of cyclin D concentration (maximum level reached in less than one
hour). In [50] experiments were realized to quantify the inverse correlation
between HiF-1α and cyclin D. Their paper shows that after 20 hours of
hypoxia (oxygen pressure P=0.21%) in a cell constitutively expressing the
cyclin D, its concentration reaches an equilibrium, and is divided by about
2 with respect to normoxia. Considering that our model describes cells that
have endured several hours of hypoxia, and that the constitutive expression is
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equivalent to the induction at the beginning of the G1 phase, the parameter
a3 was adjusted to obtain a maximal value of [cycD] divided by 2 when
P = 0.21%.
Appendix A.3. Phosphorylation of Rb
We used the model developed by [36] to adjust the parameters controlling
the quantity of phosphorylated Rb: they obtained a phosphorylation of 50%
of total Rb after 4 hours of cycle.
Appendix B. Fixed points
X∞ denotes the steady state concentration of the variableX. By equaling
to zero Eqs.(1)-(6), it is possible to calculate the equilibrium values of the
variables used in the model. The calculation of cycD∞, Rb∞, E2F∞, m∞ is
straightforward:
cycD∞ =
a1 + a3H0e
β1(1−P )
a3
Rb∞ =
d2
d2 + d1cycD∞
m∞ = m0
E2F∞ = [E2F ]total
(B.1)
By equaling to zero Eqs.(2) and (3), we obtain an equation for cycE∞:
cycE∞ =
b1m0[E2F ]tot
b2 + b3SCF∞
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and a third degree equation for SCF∞:
0 = −b3e10cycE
3
∞
+ cycE2
∞
(b3e1 − e1J2b3 − e1b2 + e2b1m0[E2F ]tot)
+ cyc∞(e1J2b3 − e1J2b2 − e2J1b1m0[E2F ]tot − e2b1m0[E2F ]tot)
+ e1J2b2 (B.2)
The equation B.2 is solved numerically, for different values of P and of
the parameters α, b1, e2. The resolution gives us the number and the values
of the fixed points; we also numerically determined the stability of these fixed
points.
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Table legends
Table 1: Parameters used in the model. The parameters we could not
estimate are initially determined in order to reach a G1 phase duration of
about 400 min for proliferative cells in normoxic conditions.
Table 2: Initial values taken for the simulations.
42
Figure legends
Figure 1: The biological switch between cyclin E and its inhibitor is
necessary to pass through the G1/S restriction point. Schematic diagram
showing the evolution of the concentration of SCF and cyc-CDK during the
cell cycle. The vertical dotted line represents the restriction point: when the
cell achieves the switch, it finishes the cycle. From [1].
Figure 2: Model of the G1/S transition in hypoxic conditions: schematic
representation of the molecular network considered in our model. We mod-
eled the action of cyclin D, which phosphorylates Rb and liberates E2F. This
transcription factor activates the synthesis of cyclin E, which is degraded by
SCF complex. HiF-1α negatively regulates cyclin D synthesis. RbNP=Non-
phosphorylated Rb.
Figure 3: Evolution of [SCF ] (solid black line) and [cycE] (solid grey
line). The simulations were made for adimensionalized values of P , with P=1
(top), 0.08 (center), 0.01 (bottom). When the molecular switch occurs, the
cell passes through the G1 phase. For P=0.01, the system does not generate
a switch any more. The cell enters into a quiescent state.
Figure 4: Influence of hypoxia on the G1 phase duration. Value of the
G1 phase duration (in min) given by the model as a function of the param-
eter P (adimensionalized).
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Figure 5: Influence of P (adimensionalized) on the stable fixed points of
the system. [SCF ]∞ (top) and [cycE]∞ (bottom) are plotted as functions of
P ∗. The dark line represent the stationary states reach by the system with
the parameters we used. The point where we pass from three to one stable
stationary state corresponds to P ∗ (limit of the quiescent state).
Figure 6: Influence of b1 (synthesis rate of cycE) and e2 (coupling be-
tween cycE and SCF ) on the value of the bifurcation point P ∗. The value
of P ∗ (color scale) is plotted as a function of b1 and e2. The white zones
correspond to non physiological values (the cell never or always finishes its
cycle).
44
